Argenx reported an unfavorable Phase 3 result for Vyvgart in Sjögren’s disease, saying the treatment did not outperform placebo on primary endpoints. The announcement adds pressure to a pipeline that had been built on autoimmune development momentum, and the company said its stock fell sharply following the news.